SETT-AID

Immunotherapies are regarded as a breakthrough in cancer therapy - highly effective, but also cost-intensive and complex. Initial studies show: Men and women respond differently. This is where the research project comes in.

The focus is on two modern approaches: CAR T-cell therapies and T-cell engagers. Both specifically attack cancer cells, but differ in their mechanism and duration of action. It is unclear whether and how biological sex influences efficacy and tolerability.

To find out, the research team is systematically analysing existing study data and, for the first time, involving patients as co-researchers. The aim is to visualise gender-specific differences in terms of the effect of therapies, side effects and quality of life, and to identify and close gaps in care.

The researchers are also investigating whether more differentiated dosage recommendations are necessary - for example due to differences in body weight or composition. The results should contribute to the development of individualised, safe therapies.